Peptide blends and stacks

Many peptides are sold two, three or four to a vial, often under a nickname. This page sets out what each common mix contains, what is known about each ingredient, and the one thing that holds for all of them except a single drug in development: nobody has studied the mix as it is sold. Nothing here is a recommendation, and no seller is named or linked.

Blend or stack?

A blend is several peptides dissolved or freeze-dried together in one vial at a fixed ratio. A stack is several separate products taken in the same period, each measured on its own. The difference matters because a blend cannot be adjusted: whatever is drawn from the vial carries every component in the vial's proportions.

Blend pages

Each composition with its own page: every ingredient's evidence and status, the ratio arithmetic, and what is and is not known about the mix.

The fixed-ratio problem

In a vial of 50 mg GHK-Cu with 10 mg each of BPC-157, TB-500 and KPV, every draw contains five times as much GHK-Cu as BPC-157. There is no way to take more of one ingredient without taking more of all of them, and no way to stop one while continuing the others. If a reaction occurs, a blend also makes it impossible to tell which ingredient caused it. Our Blend & Stack Calculator shows what any draw from a mixed vial delivers of each component.

The blends on the market, component by component

These are the 10 compositions our calculator models, each with what our encyclopedia records for every ingredient: the evidence grade, the US regulatory status, the WADA 2026 status for tested athletes, and how far the ingredient's drug interactions have been reviewed.

GHK-Cu, BPC-157, TB-500 and KPV, 80 mg (50/10/10/10)

A four-peptide composition sold under several brand names. No study has tested it as a blend. Any draw from this vial holds GHK-Cu and KPV in the ratio 50 to 10: a draw with 1 mg of KPV also contains 5 mg of GHK-Cu. Total in the vial: 80 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
GHK-Cu	50 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed
BPC-157	10 mg	Low	Research Chemical	Prohibited (S0)	Partly reviewed
TB-500	10 mg	Low	Research Chemical	Prohibited (S2.3)	Partly reviewed
KPV	10 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed

GHK-Cu, BPC-157 and TB-500, 70 mg (50/10/10)

A three-peptide composition sold under several brand names. No study has tested it as a blend. Any draw from this vial holds GHK-Cu and TB-500 in the ratio 50 to 10: a draw with 1 mg of TB-500 also contains 5 mg of GHK-Cu. Total in the vial: 70 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
GHK-Cu	50 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed
BPC-157	10 mg	Low	Research Chemical	Prohibited (S0)	Partly reviewed
TB-500	10 mg	Low	Research Chemical	Prohibited (S2.3)	Partly reviewed

BPC-157 and TB-500, 20 mg (10/10)

No study has tested this pair in people, blended or separately. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 20 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
BPC-157	10 mg	Low	Research Chemical	Prohibited (S0)	Partly reviewed
TB-500	10 mg	Low	Research Chemical	Prohibited (S2.3)	Partly reviewed

TB-500, BPC-157 and KPV, 45 mg (25/10/10)

A three-peptide composition sold under a brand name (v44: added from the Name Decoder's October 1, 2026 listing review). No study has tested it as a blend. Any draw from this vial holds TB-500 and KPV in the ratio 25 to 10: a draw with 1 mg of KPV also contains 2.5 mg of TB-500. Total in the vial: 45 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
TB-500	25 mg	Low	Research Chemical	Prohibited (S2.3)	Partly reviewed
BPC-157	10 mg	Low	Research Chemical	Prohibited (S0)	Partly reviewed
KPV	10 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed

CJC-1295 (no DAC) and ipamorelin, 10 mg (5/5)

No study has tested this pair in people. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 10 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
CJC-1295 (no DAC)	5 mg	Low	Research Chemical	Prohibited (S2.2.4)	Partly reviewed
Ipamorelin	5 mg	Medium	Discontinued	Prohibited (S2.2.4)	Partly reviewed

Tesamorelin and ipamorelin, 10 mg (5/5)

Tesamorelin is approved alone (EGRIFTA) for HIV-associated abdominal fat; this blend is not approved and has not been studied. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 10 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
Tesamorelin	5 mg	High	FDA Approved	Prohibited (S2.2.4)	Fully reviewed
Ipamorelin	5 mg	Medium	Discontinued	Prohibited (S2.2.4)	Partly reviewed

Cagrilintide and semaglutide, 10 mg (5/5)

Semaglutide is approved alone; the cagrilintide-semaglutide combination (CagriSema) is investigational, and a vial sold as this blend is neither the trial product nor approved. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 10 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
Cagrilintide	5 mg	Medium	In Clinical Trials	Prohibited under S0 (not named)	Studied
Semaglutide	5 mg	High	FDA Approved	Not on the List	Fully reviewed

Melanotan II and PT-141, 20 mg (10/10), example composition

An example pairing (v45, Q294): the two are usually sold as separate 10 mg vials and combined by the user; we found no premixed listing on October 3, 2026. PT-141 is approved alone (Vyleesi); melanotan II is unapproved; no study has tested the pair. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 20 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
Melanotan II	10 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed
PT-141	10 mg	High	FDA Approved	Not on the List	Fully reviewed

SS-31 and MOTS-c, 20 mg (10/10), example composition

An example composition (v45, Q313); we did not verify a premixed listing. SS-31 is approved alone only as Forzinity for Barth syndrome; MOTS-c is unapproved and named on the WADA list; no study has tested the pair. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 20 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
SS-31	10 mg	High	FDA Approved	Not on the List	None found in the literature
MOTS-c	10 mg	Low	Research Chemical	Prohibited (S4.4.1)	Not yet reviewed

Selank, pinealon and PE-22-28, 15 mg (5/5/5), example composition

An example composition (v45, Q313); we did not verify a premixed listing. None of the three is approved in the US; no study has tested the combination. Every component is present in equal amounts, so a draw with 1 mg of one contains 1 mg of each of the others. Total in the vial: 15 mg.

Component	In the vial	Evidence	FDA status	WADA 2026	Interactions
Selank	5 mg	Medium	Not FDA Approved	Unsettled	None found in the literature
Pinealon	5 mg	Low	Research Chemical	Prohibited under S0 (not named)	Not yet reviewed
PE-22-28	5 mg	Low	Research Chemical	Prohibited under S0 (not named)	None found in the literature

What the nicknames mean

Blends are often sold under a name rather than a list of ingredients, and the same name can mean different contents. From our Name Decoder, reviewed 2026-10-01:

Name	Usually claims	Contents as sold	The main risk
Wolverine	BPC-157, TB-500	Usually BPC-157 and TB-500 together, often 10 mg of each. The name is also used for BPC-157 alone and for the four-peptide KLOW mix.	Neither component is FDA-approved, and WADA names both on its Prohibited List.
KLOW	GHK-Cu, BPC-157, TB-500, KPV	Usually GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg in one 80 mg vial. At least one listing reverses the GHK-Cu and BPC-157 amounts.	No published study has tested this mix, and none of its four components is FDA-approved.
GLOW	GHK-Cu, BPC-157, TB-500	GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg in one 70 mg vial: KLOW without the KPV.	No published study has tested this mix, and none of its components is FDA-approved.
Tri-Heal	TB-500, BPC-157, KPV	TB-500 25 mg, BPC-157 10 mg and KPV 10 mg in one 45 mg vial.	No published study has tested this mix, and none of its components is FDA-approved.

Why none is studied as one

9 of the 10 compositions above have no published study of the mix: not the four- and three-peptide vials, not BPC-157 with TB-500, and not the growth-hormone pairs. Tesamorelin is approved on its own as EGRIFTA for HIV-associated abdominal fat (what its trials show), but not combined with ipamorelin. The last, cagrilintide with semaglutide, is the exception: it was studied as Novo Nordisk's CagriSema, at the company's own doses and manufacturing standards, and a vial sold under that name is neither the trial product nor an approved drug. A study of each ingredient alone does not tell anyone what happens when they are combined, at a fixed ratio, from an unregulated vial.

Before using any mix, the questions worth asking are the ones in the Name Decoder: which peptides, how many milligrams of each, and what a certificate of analysis actually shows. Our COA Decoder explains how to read one, and the Interaction Matrix shows what is recorded for each ingredient.

Most of these blends are sold for injuries. For what has actually been tested in people with tendon and ligament problems, see peptides for tendon and ligament injuries, ranked, and for recovery from an operation, what the studies and surgeons say. Blends are also sold for pets; BPC-157 for dogs covers why that has no veterinary evidence.

The CJC-1295 in growth-hormone blends is usually not the CJC-1295 that was tested in people: CJC-1295 with vs without DAC explains the difference.